復(fù)方丹參滴丸與芪參益氣滴丸在冠心病臨床中的治療分析
【摘要】目的:研究復(fù)方丹參滴丸與芪參益氣滴丸在冠心病臨床中的治療效果。方法:選擇2021年5月—2022年5月我院收治的78例冠心病患者,隨機(jī)分為研究組與對(duì)照組,每組39例。對(duì)照組采用芪參益氣滴丸治療,研究組應(yīng)用復(fù)方丹參滴丸治療,對(duì)比兩組臨床療效、治療前后心功能能指標(biāo)、生活質(zhì)量評(píng)分。結(jié)果:研究組治療總有效率高于對(duì)照組;治療后研究組的 FS、 LVEF 更高,LVESV、LVEDV、LVDs、LVDd更低;研究組生活質(zhì)量評(píng)分高于對(duì)照組,數(shù)據(jù)對(duì)比有意義(P
【關(guān)鍵詞】復(fù)方丹參滴丸;芪參益氣滴丸;冠心??;心功能指標(biāo);生活質(zhì)量
Clinical analysis of compound Danshen dripping pills and Qishenyiqi dripping pills in the treatment of coronary heart disease
GAO Jianping
Qingshui People’s Hospital of Gansu Province, Tianshui, Gansu 741400, China
【Abstract】Objective: To study the clinical therapeutic effect of compound Danshen dripping pills and Qishenyiqi dripping pills on coronary heart disease. Methods: 78 patients with coronary heart disease admitted to our hospital from May 2021 to May 2022 were randomly divided into study group and control group, with 39 cases in each group. The control group was treated with Qishenyiqi dripping pills, and the study group was treated with compound Danshen dripping pills. The clinical efficacy, cardiac function indexes and quality of life scores before and after treatment were compared between the two groups. Results: The total effective rate of the study group was higher than that of the control group. FS and LVEF were higher in the study group after treatment, while LVESV, LVEDV, LVDs and LVDd were lower. The quality of life score of the study group was higher than that of the control group(P
【Key Words】Compound Salvia miltiorrhiza dripping pills; Qishenyiqi dropping pill; Coronary heart disease; Cardiac function index; Quality of life
冠狀動(dòng)脈粥樣硬化性心臟病又被稱之為冠心病,主要是因?yàn)檠軆?nèi)脂質(zhì)異常所致血管狹窄或阻塞,繼而出現(xiàn)缺氧、缺血等情況,患者的臨床癥狀相對(duì)比較明顯,以心悸、氣短、胸痛、心絞痛等為主要表現(xiàn)[1]。(剩余3552字)
- 層級(jí)式責(zé)任制管理在兒科護(hù)理管理...
- 藍(lán)光聯(lián)合腺苷蛋氨酸治療新生兒黃...
- 嬰幼兒早期發(fā)育中運(yùn)用正確兒童保...
- 中西醫(yī)結(jié)合治療宮腔粘連合并胎骨...
- 研究子宮內(nèi)膜病變患者應(yīng)用經(jīng)陰道...
- 經(jīng)陰道彩色多普勒超聲對(duì)子宮內(nèi)膜...
- 多囊卵巢綜合征致不孕患者應(yīng)用氯...
- 子宮肌瘤應(yīng)用B超鑒別診斷的價(jià)值...
- 輸卵管積液的CT及MRI影像學(xué)...
- 乳腺超聲檢查診斷乳腺腫瘤的特異...
- 陰道炎五聯(lián)檢驗(yàn)在白帶常規(guī)檢驗(yàn)中...
- 循證護(hù)理應(yīng)用于腹腔鏡下宮頸癌術(shù)...
- 全程規(guī)范化護(hù)理在卵巢癌植入式靜...
- 個(gè)性化綜合護(hù)理在妊娠期糖尿病中...
- 系統(tǒng)性心理干預(yù)在骨折護(hù)理中的應(yīng)...
- 個(gè)性化護(hù)理在癌癥患者化療期間P...
- 綜合護(hù)理干預(yù)用于呼吸科肺栓塞護(hù)...
- 隨訪護(hù)理伴CGA對(duì)高血壓合并糖...
- 消化內(nèi)科常見護(hù)理風(fēng)險(xiǎn)及臨床防范...
- 延續(xù)性護(hù)理干預(yù)對(duì)PCI治療的冠...
- 針對(duì)性護(hù)理干預(yù)對(duì)前交叉韌帶重建...
- 口腔護(hù)理結(jié)合飲食干預(yù)對(duì)口腔潰瘍...
- 基于健康信念模式的護(hù)理干預(yù)在房...
- 細(xì)節(jié)護(hù)理在顱腦外傷患者護(hù)理中的...
- 快速康復(fù)外科理念在老年人人工髖...
- 家庭成員互動(dòng)護(hù)理對(duì)鄉(xiāng)鎮(zhèn)衛(wèi)生院糖...
- 病毒性心肌炎患者護(hù)理中應(yīng)用綜合...
- 舒適護(hù)理在肝癌患者介入護(hù)理中的...
- 個(gè)體化護(hù)理在人工髖關(guān)節(jié)置換術(shù)的...
- 早期社區(qū)護(hù)理干預(yù)對(duì)糖尿病足發(fā)生...
- 急性閉塞性腦梗死介入溶栓術(shù)的護(hù)...
- 飲食管理配合個(gè)體化認(rèn)知行為護(hù)理...
- 麻醉護(hù)理一體化管理模式對(duì)麻醉后...
- 共情護(hù)理對(duì)艾滋病患者抗病毒治療...
- 提高婦女兩癌篩查意愿開展健康宣...
- 情景模擬帶教在內(nèi)分泌科護(hù)理教學(xué)...
- 信息化2.0時(shí)代口腔醫(yī)學(xué)教學(xué)的...
- 自我效能干預(yù)在化療間歇期留置P...
- 經(jīng)皮冠狀動(dòng)脈介入術(shù)中注射重組人...
- 椎板間隙入路脊柱內(nèi)鏡技術(shù)治療老...
- CT聯(lián)合X線在肺結(jié)核患者中的診...
- 彩色多普勒超聲診斷急性附睪炎的...
- 心臟超聲診斷高血壓左室肥厚伴左...
- 溶血對(duì)肝功能檢驗(yàn)的臨床影響...
- 微創(chuàng)不翻瓣技術(shù)在口腔種植手術(shù)中...
- 前庭康復(fù)治療急性前庭神經(jīng)炎的效...
- 丁苯酞軟膠囊對(duì)急性腦梗死伴輕度...
- 米非司酮用于治療婦產(chǎn)科疾病的臨...
- 尼莫地平與氟桂利嗪治療偏頭疼的...
- 比索洛爾聯(lián)合沙庫巴曲纈沙坦治療...
- 二甲雙胍聯(lián)合吡格列酮對(duì)糖尿病患...
- 卡格列凈聯(lián)合吡格列酮治療2型糖...
- 孟魯司特鈉聯(lián)合硫酸沙丁胺醇治療...
- 氣囊仿生助產(chǎn)聯(lián)合分娩鎮(zhèn)痛護(hù)理模...
- 飲食及運(yùn)動(dòng)聯(lián)合干預(yù)在妊娠期糖尿...
- 不孕癥病人實(shí)施性激素檢驗(yàn)的方法...
- 流產(chǎn)后關(guān)愛在意外妊娠流產(chǎn)后護(hù)理...
- 高危孕產(chǎn)婦管理對(duì)孕產(chǎn)婦和新生兒...
- 和血明目片對(duì)糖尿病視網(wǎng)膜病變的...
- 中藥外敷配合四妙散加減治療痛風(fēng)...
- 中醫(yī)傳統(tǒng)療法聯(lián)合康復(fù)理療對(duì)腰椎...
- 穴位按摩聯(lián)合手法淋巴引流在產(chǎn)后...
- 復(fù)方丹參滴丸與芪參益氣滴丸在冠...
- 中藥熏洗配合甲鈷胺片應(yīng)用于治療...
- 中西醫(yī)結(jié)合治療原發(fā)性骨質(zhì)疏松癥...
- 中西醫(yī)結(jié)合治療老年風(fēng)濕病臨床觀...